Therapeutic antibodies of targeting the programmed cell death protein 1(PD-1)/programmed death-ligand 1(PD-L1)pathway are used in hepatocellular carcinoma(HCC)treatment,but are limited by low response rates and immune...Therapeutic antibodies of targeting the programmed cell death protein 1(PD-1)/programmed death-ligand 1(PD-L1)pathway are used in hepatocellular carcinoma(HCC)treatment,but are limited by low response rates and immune-related toxicity[1].Searching for treatment approaches to combine with PD-1/PD-L1 blockade may potentially enhance the efficacy of PD-1/PD-L1 blockade and reduce its side effects.展开更多
基金National Natural Science Foundation of China(Grant Nos.:82274154,82304792)Natural Science Foundation of Tianjin Municipality(GrantNos.:23JCzXJC00150+1 种基金23JCJQjC00040)China Postdoctoral Science Foundation(Grant Nos.:2023M732627,2024T170657).
文摘Therapeutic antibodies of targeting the programmed cell death protein 1(PD-1)/programmed death-ligand 1(PD-L1)pathway are used in hepatocellular carcinoma(HCC)treatment,but are limited by low response rates and immune-related toxicity[1].Searching for treatment approaches to combine with PD-1/PD-L1 blockade may potentially enhance the efficacy of PD-1/PD-L1 blockade and reduce its side effects.
